Goodwin’s Life Sciences team advised aTyr Pharma, Inc. in its definitive securities purchase agreement with certain institutional and other accredited investors including members of the Company’s Board of Directors. Gross proceeds from the private placement are expected to be approximately $45.8 million. aTyr expects to use the proceeds from the transaction primarily to advance its pipeline of innovative therapeutic candidate programs based on its knowledge of the Resokine pathway, and for general corporate purposes.
aTyr Pharma is a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics, harnessing the Resokine pathway, to treat patients suffering from severe, rare immune-mediated diseases, as well as various cancers.
For additional details on the transaction, please read the press release.